Capital Advisors Ltd’s Alnylam Pharmaceuticals ALNY Stock Holding History

Capital Advisors Ltd’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$49K	Sell	162 -1	-0.6%	-$302	﹤0.01%	511
2026 Q1	$54K	Buy	163 +1	+0.6%	+$340	0.01%	476
2025 Q4	$64K	Hold	162	–	–	0.01%	444
2025 Q3	$74K	Hold	162	–	–	0.01%	416
2025 Q2	$53K	Hold	162	–	–	0.01%	456
2025 Q1	$44K	Hold	162	–	–	0.01%	481
2024 Q4	$38K	Hold	162	–	–	﹤0.01%	501
2024 Q3	$45K	Hold	162	–	–	0.01%	469
2024 Q2	$39K	Buy	162 +2	+1%	+$316	0.01%	484
2024 Q1	$24K	Buy	160 +2	+1%	+$334	﹤0.01%	554
2023 Q4	$30K	Sell	158 -15	-9%	-$2.56K	﹤0.01%	498
2023 Q3	$31K	Buy	173 +15	+9%	+$2.86K	﹤0.01%	479
2023 Q2	$30K	Buy	158 +148	+1,480%	+$29.3K	﹤0.01%	498
2023 Q1	$2K	Sell	10 -158	-94%	-$33.2K	﹤0.01%	861
2022 Q4	$2K	Buy	168 +151	+888%	+$32.2K	﹤0.01%	816
2022 Q3	$3K	Buy	+17	New	+$3.24K	﹤0.01%	717
2022 Q2	–	Sell	-4	Closed	-$1K	–	978
2022 Q1	$1K	Buy	4 +3	+300%	+$457	﹤0.01%	665
2021 Q4	$0	Buy	+1	New	+$186	﹤0.01%	799

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Advisors Ltd's ALNY Position: Q2 2026 in Review

Capital Advisors Ltd reduced its Alnylam Pharmaceuticals (ALNY) stake by 0.61% in Q2 2026, selling an estimated $302 and leaving 162 shares worth $49K. The position accounts for ﹤0.01% of the portfolio, ranked #511.

Capital Advisors Ltd first reported a position in ALNY in Q4 2021 and has held it in 18 quarters since. The position peaked at $74K in Q3 2025. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Capital Advisors Ltd held 162 shares of Alnylam Pharmaceuticals worth $49K as of Q2 2026.
Capital Advisors Ltd sold 1 Alnylam Pharmaceuticals share in Q2 2026, an estimated $302.
Alnylam Pharmaceuticals made up ﹤0.01% of Capital Advisors Ltd's portfolio in Q2 2026, its #511 holding.
Capital Advisors Ltd first reported a position in Alnylam Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
Capital Advisors Ltd's Alnylam Pharmaceuticals position peaked at $74K in Q3 2025.
785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Capital Advisors Ltd's 13F filing for Q2 2026, filed 16 Jul 2026.